🟢 20/20 Biolabs is trading 5.9% up in pre-market after Q2 revenue rose 36.5%

20/20 Biolabs is trading at $0.54, +5.9% in pre-market after Q2 revenue rose 36.5% year over year.

• Revenue reached $0.7 million, while gross margin expanded to 41.7%.
• The stock is up from the $0.51 August 19 close.
• The report showed a wider $1.5 million net loss and $0.26 per-share loss; strength likely reflects investors weighing record testing volume and margin improvement against the earnings loss.